118. The Synthesis of 5, 11, 17-Trihalotetracyclo [13.3.1.1^{3,7}.1^{9,13}]henicosa-1 (19), 3, 5, 7 (20), 9, 11, 13 (21), 15, 17-nonaene-19, 20, 21-triols and 5, 11, 17-Trihalo-19, 20, 21-trihydroxytetracyclo [13.3.1.1^{3,7}.1^{9,13}]henicosa-1 (19), 3, 5, 7 (20), 9, 11, 13 (21), 15, 17-nonaene-8, 14-dione [1]. Cyclo-derivatives of Phloroglucide Analogues

by Ali A. Moshfegh, Effat Beladi, Lida Radnia, Afsaneh S. Hosseini, Soosan Tofigh and Gholam H. Hakimelahi¹)

Department of Chemistry, Shiraz University, Shiraz, Iran

(4.1.82)

Summary

The synthesis of the title compounds (1 and 3) is described. Some of the compounds prepared were found to be active against a number of pathogenic microorganisms *in vitro*. Structure-activity relationship is briefly discussed.

Lindsey has found that the acid-catalyzed condensation of veratrole with formaldehyde gave cyclotriveratrylene (= 5, 6, 12, 13, 19, 20-hexamethoxytetracyclo-[15.4.0.0^{3,8}.0^{10,15}]henicosa-1 (17), 3 (8), 4, 6, 10 (15), 11, 13, 18, 20-nonaene) [2]. The parent ring system I was similarly named cyclotribenzylene (= tetracyclo-[15.4.0^{3,8}.0^{10,15}]henicosa-1 (17), 3 (8), 4, 10 (15), 11, 13, 18, 20-nonaene) [2]. The conformation of cyclotriveratrylene was investigated using molecular models combined with ¹H-NMR. measurements [3].

In the previous papers [4] [5] we described the synthesis of halogenated derivatives of phloroglucide analogues as well as of their cyclic analogues [6] containing four phenolic units and having the general structure II. The compounds



¹) Author to whom correspondence should be addressed. Present address: Department of Chemistry, McGill University, 801 Sherbrooke St. W., Montreal, Quebec, Canada H3A 2K6. II are active against a number of pathogenic microorganisms *in vitro*. In this paper we report the synthesis and antimicrobial properties of the cyclic analogues 1-3 containing three phenolic units and having functionality similar to that of phloroglucides $[7]^2$).

In a model reaction, 4-chloro-2, 6-bis (hydroxymethyl)phenol (4a) [5] was reacted with 4,4'-dichloro-2,2'-methylenediphenol (5a) [4] and HCl to give 5,11,17-trichlorometacyclotribenzylene-19,20,21-triol (1a) in high yield. The ¹H-NMR., IR., UV., electron impact and chemical ionization mass spectra and the microanalysis of 1a were consistent with the proposed structure.

Using the same procedure, 4-chloro-2, 6-bis (hydroxymethyl)phenol (4a), 4-fluoro-2, 6-bis (hydroxymethyl)phenol (4b) and 4-bromo-2, 6-bis (hydroxymethyl)phenol (4c) were transformed to the corresponding cyclic compounds 1b-i by reaction with the 4, 4'-dihalo-2, 2'-methylenediphenol 5a-c and HCl. Conversion of 1c, 1f, 1g, 1h and 1i to 2a-e, respectively, was achieved in good yield by treatment with Zn/KOH [4].

Since the oxidation of the CH_2 -bridges to carbonyl functions may increase the chelating ability, the derivatives 3a-i were prepared from 1a, 1d, 1g, 1i and 2a-e

Compound ^a)	(MW)	m.p. [°C]	Yield [%]	$MS.(M^+)$		
1a	(C ₂₁ H ₁₅ Cl ₃ O ₃ , 421.84)	225-227	71	420 (Cl-clusters)		
1b	(C ₂₁ H ₁₅ ClF ₂ O ₃ , 388.50)	189-190	90	388 (Cl-cluster)		
1c	$(C_{21}H_{15}Br_2ClO_3, 430.41)$	156-158	76	429 (Cl, Br-clusters)		
1d	$(C_{21}H_{15}Cl_2FO_3, 405.11)$	212-214	87	404 (Cl-clusters)		
le	$(C_{21}H_{15}F_{3}O_{3}, 372.00)$	160-163	80	372		
1f	(C ₂₁ H ₁₅ Br ₂ FO ₃ , 413.91)	145-147	85	412 (Br-clusters)		
1g	$(C_{21}H_{15}BrCl_2O_3, 466.34)$	218-220	70	464 (Cl, Br-clusters)		
1h	$(C_{21}H_{15}BrF_2O_3, 432.98)$	205-208	70	431 (Br-cluster)		
1 i	(C ₂₁ H ₁₅ Br ₃ O ₃ , 554.93)	210 (dec.)	69	552 (Br-clusters)		
2a	$(C_{21}H_{17}ClO_3, 352.50)$	160-162	24	352 (Cl-cluster)		
2 b	(C ₂₁ H ₁₇ FO ₃ , 336.00)	155-157	35	336		
2c	(C ₂₁ H ₁₆ Cl ₂ O ₃ , 387.12)	193-196	95	386 (Cl-clusters)		
2 d	$(C_{21}H_{16}F_2O_3, 354.32)$	170-172	90	354		
2e	(C ₂₁ H ₁₈ O ₃ , 318.00)	151-152	68	318		
3a	$(C_{21}H_{18}Cl_{3}O_{5}, 450.62)$	180-183	50	449 (Cl-clusters)		
3b	(C ₂₁ H ₁₈ Cl ₂ FO ₅ , 432.90)	176-177	60	431 (Cl-clusters)		
3c	$(C_{21}H_{11}BrCl_2O_5, 493.98)$	200-202	58	492 (Cl, Br-clusters)		
3d	$(C_{21}H_{11}Br_3O_5, 583.00)$	250 (dec.)	40	580 (Br-clusters)		
3e	$(C_{21}H_{13}ClO_5, 380.50)$	108-109	30	380 (Cl-clusters)		
3f	(C ₂₁ H ₁₃ FO ₅ , 364.00)	200 (dec.)	53	364		
3g	$(C_{21}H_{12}Cl_2O_5, 415.32)$	178-180	80	414 (Cl-clusters)		
3h	$(C_{21}H_{12}F_2O_5, 382.15)$	161-162	65	382		
3i	$(C_{21}H_{14}O_5, 346.14)$	140-142	75	346		

Table 1. Properties of metacyclotribenzylenes 1-3

²) The systematic name of *e.g.* **1a** is 5,11,17-trichlorotetracyclo[13.3.1,1^{3,7},1^{9,13}]henicosa-1(19),3,5, 7(20),9,11,13(21),15,17-nonaene-19,20,21-triol and of *e.g.* **3a** 5,11,17-trichloro-19,20,21-trihydroxy-tetracyclo[13.3.1,1^{3,7},1^{9,13}]henicosa-1(19),3,5,7(20),9,11,13(21),15,17-nonaene-8,14-dione. For convenience we call the parent structure metacyclotribenzylene [8].

Com-	Purification Method	Calc.	%]		Found	l [%]	
pound		C	Ĥ	Halogen	С	H	Halogen
la	Sublimation (190°/0.01 Torr)	60.00	3.57	25.00 (Cl)	59.91	3.61	25.04 (Cl)
1b	Sublimation (173°/0.01 Torr)	64.86	3.86	9.14 (Cl) 9.78 (F)	64.77	3.81	9.05 (Cl) 9.80 (F)
1c	Crystallization (CHCl ₃)	-	-	-	-	-	-
1d	Sublimation (200°/0.01 Torr)	62.25	3.70	17.50 (Cl) 4.69 (F)	62.17	3.72	17.25 (Cl) 4.58 (F)
1e	Sublimation (160°/0.01 Torr)	67.74	4.03	15.32 (F)	67.71	4.01	15.29 (F)
lf	Crystallization (ether)	-		-	-	-	-
1g	Sublimation (180°/0.01 Torr)	54.07	3.21	17.16 (Br)	54.27	3.13	16.98 (Br)
lh	Chromatography (silica gel, EtOAc)	-	-	-	-	-	
1i	Crystallization (ether)	45.51	2.70	43.24 (Br)	54.22	2.88	43.21 (Br)
2a	Sublimation (165°/0.01 Torr)	71.59	4.82	10.08 (Cl)	71.98	4.71	10.18 (Cl)
2b	Sublimation (185°/0.01 Torr)	75.00	5.06	5.65 (F)	74.99	5.15	5.61 (F)
2c	Sublimation (180°/0.01 Torr)	65.11	4.13	18.34 (Cl)	64.99	3.98	18.21 (Cl)
2d	Sublimation (168°/0.01 Torr)	71.19	4.52	10.73 (F)	71.21	4.62	10.64 (F)
2e	Sublimation (185°/0.01 Torr)	79,20	5.60	-	79.18	5.68	-
3a	Sublimation (175°/0.01 Torr)	56.25	2.45	23.43 (Cl)	56.15	2,36	23.36 (Cl)
3b	Sublimation (165°/0.01 Torr)	58.23	2.53	16.36 (Cl)	58.21	2.56	16.51 (Cl)
				4.38 (F)			4.28 (F)
3c	Chromatography (silica gel, EtOAc)		-		-	-	-
3 d	Crystallization (EtOAc)	-	-	-	-	-	-
3e	Crystallization (CH ₂ Cl ₂)	66.23	3.42	9.33 (Cl)	66.21	3.48	9.09 (Cl)
3f	Sublimation (149°/0.01 Torr)	69.23	3.57	5.22 (F)	69.22	3.57	5.23 (F)
3g	Sublimation (170°/0.01 Torr)	60.72	2.89	17.11 (Cl)	60.59	2.99	17.18 (Cl)
3h	Sublimation (156°/0.01 Torr)	65.96	3.14	9.94 (F)	65.93	3.09	10.00 (F)
3i	Sublimation (159°/0.01 Torr)	72.83	4.04	_	72.81	4.07	_

Table 2. Purification conditions and elemental analyses of metacyclotribenzylenes 1-3

by the action of CrO_3/Ac_2O [4] followed by hydrolysis of the ester groups. It should be noted that the oxidation of all three CH_2 -bridges in compounds 1 and 2 were impossible due to the highly strained macrocyclic ring in 3.

The purification conditions, the properties and elemental analyses of all products 1-3 are summarized in *Tables 1* and 2. All compounds 1-3 were tested *in vitro* against *S. aureus, E. coli, C. albicans* and *Ps. aeruginosa* up to 128 μ g/ml. Some of them showed notable activity against the above bacteria (*Table 3*). When a (1:1)-mixture of compounds 1d and 2c was prepared and tested against the above microorganisms, an interesting antimicrobial activity was observed in the case of *Ps. aeruginosa* (experiment No.5, *Table 3*). Owing to the fact that there is no explanation for the behavior of 1d/2 c, studies in this area are underway.

No.	Compound	S. aureus	E. coli	C. albicans	Ps. aeruginosa	
1	1a	0.1		128	_	
2	1d	30	1.5	3	1	
3	2c	0.1	> 128	15	-	
4	3g	30	100	>128	-	
5	1d/2c 1:1	1.5	3	6	0.1	

Table 3. Minimal inhibitory concentrations [µg/ml]

It has been previously shown that the presence of heavy metal ions plays an important role in the effect and mechanism of action of certain antibiotics against the growth of some bacteria [9-11]. The biological tests on our compounds suggest that the structural features of macrocycles 1 and 2 necessary for antimicrobial activity are at least the two chlorophenolic units. Examples include 1a and 1d possessing fluorine and chlorine atoms, in contrast to the bromo-substituted derivative 1g. However, when 1g was debrominated, the bioactive compound 2c was obtained. The reasons for the inactivity of bromo derivatives are not known, but this inactivity has been noticed previously [4-6]. When 2c is replaced by 3g, biological activity decreases. All the other analogues are inactive against the growth of bacteria. These results suggest that in addition to chelating abilities, a variety of other factors must be considered. Therefore, it is difficult to rank the order of biological activity accurately. However, some observations on structure and activity relationship can be made.

Model studies indicate that the steric requirements of the three active compounds 1a, 1d and 2c favor the 'crown' conformation III. The H-bonded hydroxyl groups (\tilde{v}_{max} 3200 cm⁻¹) lie close together at the apex. This is confirmed by ¹H-NMR. investigations which show that the methylene protons in 1a, 1d and 2c are nonequivalent and appear as doublets at about 4.53 (J = 12 Hz) and 3.82 (J = 12 Hz) ppm. In such a rigid 'crown' conformation the hydroxy groups would be in a suitable spatial arrangement for chelate formation with metal ions of enzymes. Indeed, 1a, 1d and 2c show a strong tendency for chelation with cations (*i.e.* FeCl₃). Esterification of the hydroxy functions results in loss of both chelating ability and biological activity.



When two CH₂-bridges are oxidized to carbonyl functions as in 3a, 3b and 3g, the biological activity is either drastically diminished or lost. ¹H-NMR. spectra of 3a, 3b and 3g show the two nonequivalent methylene protons as doublets at about 4.87 (J=15 Hz) and 4.01 (J=15 Hz) ppm. IR. spectra exhibit two different types of carbonyl groups (1630, 1603 cm⁻¹), and the signal of free hydroxyl functions appear at 3500-3300 cm⁻¹. These spectroscopic results and model studies indicate that 3 must possess the rigid conformation IV. The space-filling models (*Figure*) of 3 indicate also that the conformation III is unlikely. As the conformational transformation III \rightarrow IV is not feasible, conformation IV of 3 might be built up during the oxidation of 1 to 3 by the oxidation followed by the scission of the methylene-aryl C, C-bond, subsequent recombination [12–14]. Although the compounds 3 exhibit tendency for chelation with some cations (*i.e.* FeCl₃),



1a, conformation III (top view)



1a, conformation III (bottom view)



3a, conformation IV (top view)



3a, conformation IV (bottom view)

Figure. Space-filling molecular models of compounds 1a and 3a.

apparently, the functional groups are not in a suitable spatial arrangement (s. IV) for chelate formation with metal ions of enzymes, (loss of biological activity). It should be noted that when the hydroxy groups in 3 were acetylated, the carbonyl group absorbed in the IR. at 1676 cm⁻¹ as a sharp singlet and the ester groups at 1771 cm^{-1} .

These findings suggest that metal chelation as well as the spatial disposition of the various groups and the structural conformations are important in fitting the molecule in an enzyme site. However, further studies are required to establish a definite structure-activity relationship.

We are grateful to Mrs. N.C. Behforouz who carried out the biological tests at the School of Medicine, Shiraz University, Iran.





1a R = Cl,

1c R = Br,

1d R = Cl,

1e R = F,

1f R = Br,

1g R = Cl.

1h R = F,

1 R = Br,

1b R = F



5c R = Br

Experimental Part

General Procedures. See [4].

Synthesis of the metacyclotribenzylenes 1a-i. They were all prepared in the same manner we give as an example the preparation of 5,11,17-trichlorometacyclotribenzylene-19,20,21-triol (1a). To a solution of 4a (1.84 g, 0.01 mol) and 5a (5.4 g, 0.02 mol) in methanol (20 ml) was added concentrated hydrochloric acid (5 ml). The mixture was shaken at 60-85° for 45 min and then allowed to stand at 25° for 24 h. The solution was evaporated and the residue suspended in boiling water to dissolve unreacted starting materials. The precipitate was filtered off, washed with water and dried to give 6.2 g (71%) of 1a - IR. (KBr): 3200 br., 1586w, 1485s, 1450s, 1390m, 1255m, 1230s, 1180w, 930w and 810w. – ¹H-NMR. (CDCl₃): 9.41 (br., 3 H, 3 HO, exchangeable with D₂O); 7.09 (s, 6 H, 6 arom. H); 4.53 (d, J = 12, 3 H, 3 HCH); 3.82 (d, J = 12, 3 H, 3 HCH).

Synthesis of the trihydroxydiones 3a-i. They were all prepared in the same manner as given for the preparation of 5,11,17-trichloro-19,20,21-trihydroxy-metacyclotribenzylene-8,14-dione (3a). Compound 1a (2 g, 4 mmol) was dissolved in acetic anhydride (15 ml). One drop of concentrated sulfuric acid was added and the mixture heated under reflux for 2 h. A solution of CrO_3 (1.9 g) in $Ac_2O/AcOH$ 3:1 (20 ml) was added dropwise within 2 h at 25° with continuous stirring. The mixture was kept at 45° for 4 h, and then heated under reflux for 2 h. After cooling, it was poured into cold water (200 ml) and allowed to stand for 15 h. The yellow precipitate was filtered off, washed with water and dried (2.2 g). The product was dissolved in 10% aq. NaOH-solution (50 ml) and heated at 45° for 1.5 h. The solution was filtered, and the filtrate acidified with 2N HCl to give a pale yellow precipitate which was filtered off, washed with water and dried to afford 1.28 g (50%, based on 1a) of 3a. – IR. (KBr): 3500–3300 br., 1630s, 1603s, 1490m, 1430s, 1345m, 1240s, 1170w, 1030m, 810m. – ¹H-NMR. (CDCl₃): 8.98 (br., 1 H, HO, exchangeable with D₂O); 8.60 (br., 2 H, 2 HO, exchangeable with D₂O); 7.11-7.48 (m, 6 H, 6 arom. H); 4.87 (d, J = 15, 1 H, HCH); 4.01 (d, J = 15, 1 H, HCH).

REFERENCES

- [1] A.A. Moshfegh, Swiss Patent, No. 7448 (1978).
- [2] A.S. Lindsey, Chem. Ind. (London) 1963, 823.
- [3] H. Erdtman, F. Haglid & R. Ryhage, Acta Chem. Scand. 18, (1964) 1249.
- [4] G. H. Hakimelahi & A. A. Moshfegh, Helv. Chim. Acta 64, 599 (1981).
- [5] A.A. Moshfegh, B. Mazandarani, A. Nahid & G.H. Hakimelahi, Helv. Chim. Acta, in press.
- [6] A.A. Moshfegh, R. Badri, M. Hojjatie, M. Kaviani, B. Naderi, A.H. Nazmi, M. Ramezanian, B. Roozpeikar & G.H. Hakimelahi, Helv. Chim. Acta, in press.
- [7] M. Lounasmaa, C.J. Widen & T. Reichstein, Helv. Chim. Acta 56, 1133 (1973).
- [8] J. W. Cornforth, P. D'Arcy Hart, G.A. Nicholls, R.J. W. Rees & J.A. Stock, Br. J. Pharmacol. 10, 73 (1955).
- [9] E. Sorkin, W. Roth & H. Erlenmeyer, Experientia 7, 64 (1951); E. Sorkin, W. Roth, V. Kocher & H. Erlenmeyer, Experientia 7, 257 (1951).
- [10] S. D. Rubbo, A. Albert & N.I.J. Gibson, Exper. Path. 31, 425 (1950).
- [11] E. Sorkin, W. Roth & H. Erlenmeyer, Helv. Chim. Acta 35, 1736 (1952); S. Fallab, Helv. Chim. Acta 36, 6 (1953).
- [12] R.O.C. Norman & R. Taylor, 'Electrophilic Substitution in Benzenoid Compounds', Elsevier, Amsterdam 1965, pp. 57-58 and Chap. 6 (sect. 1).
- [13] M.S. Kharasch & J. Porsche, J. Org. Chem. 1, 265 (1936); A. Burawoy & J.T. Chamberlain, J. Chem. Soc. 1949, 626.
- [14] A. G. S. Hogberg, J. Am. Chem. Soc. 102, 6046 (1980).